Purification, Properties, Sequencing, and Cloning of a Lipoprotein-Associated, Serine-Dependent Phospholipase Involved in the Oxidative Modification of Low-Density Lipoproteins

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 4, 1996, Pages 591-599

  Tew, David G ^a   Southan, Christopher ^b   Rice, Simon Q J ^d   Lawrence, G Mark P ^d   Li, Haodong ^e   Boyd, Helen F ^a   Moores, Kitty ^c   Gloger, Israel S ^d   Macphee, Colin H ^a,c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Protein Chemistry

^c Vascular Biology

^d Department of Biotechnology ^*  (United Kingdom)

^e GLAXOSMITHKLINE   (United States)

Author keywords

LDL; Oxidation; PAF AH; Phospholipase A2

Indexed keywords

LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE; SERINE;

ARTICLE; BACULOVIRUS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; GENE TRANSLOCATION; ION EXCHANGE CHROMATOGRAPHY; LIPID OXIDATION; MOLECULAR CLONING; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; SOLUBILIZATION;

AMINO ACID SEQUENCE; AORTIC VALVE STENOSIS; BACULOVIRIDAE; BASE SEQUENCE; CLONING, MOLECULAR; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; PHOSPHOLIPASES A; SERINE;

EID: 0029986601     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.4.591     Document Type: Article

References (39)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
2. Berliner JA, Haberland MA. The role of low density lipoprotein in atherogenesis. Curr Opin Lipidol. 1993;4:373-381.
3. Holvoet P, Collen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB J. 1994;8:1279-1284.
4. 2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci U S A. 1985;82:3000-3004.
5. Parthasarathy S, Barnett J. Phospholipase A2 activity of low density lipoprotein: evidence for an intrinsic phospholipase A2 activity of apoprotein B-100. Proc Natl Acad Sci USA. 1990;87:9741-9745.
6. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988;85:2805-2809.
7. Kume N, Cybulsky MI, Gimbrone MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 1992;90:1138-1144.
8. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low density lipoproteins. Nature. 1990;344:160-162.
9. Liu S-Y, Lu X, Choy S, Dembinski TC, Hatch GM, Mymin D, Shen X, Angel A, Choy PC, Man RYK. Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation. Cardiovasc Res. 1994;28:1476-1481.
10. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Ohta Y, Yasue H. LPC in oxidized LDL elicits vasoconstriction and inhibits endothelium-dependent relaxation. Am J Physiol. 1994;267:H2441-H2449.
11. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase: association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem. 1987;262:4215-4222.
12. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: oxidatively fragmented phospholipids as substrates. J Biol Chem. 1991;266:11095-11103.
13. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, Hooper S, Le Trong H, Cousens LS, Zimmerman GA, Yamada Y, McIntyre TM, Prescott SM, Gray PW. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 1995;374:549-553.
14. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: purification and properties. J Biol Chem. 1987;262:4223-4230.
15. Curran ME, Atkinson DL, Ewart AK, Morris CA, Leppert MF, Keating MT. The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis. Cell. 1993;73:159-168.
16. 2 assay. J Am Chem Soc. 1990;112:2040-2041.
17. Macphee CH, Harrison SA, Beavo JA. Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents. Proc Natl Acad Sci U S A. 1986;83:6660-6663.
18. Tarentino AL, Plummer TH. PNGase F. Methods Enzymol. 1987;138:777-778.
19. Crimmins DL, McCourt DW, Thoma RS, Scott MG, Macke K, Schwartz BD. In situ chemical cleavage of proteins immobilized to glass-fiber and polyvinylidenedifluoride membranes: cleavage at tryptophan residues with 2-(2′-nitrophenylsulfenyl)-3-methyl-3′-bromoindolenine to obtain internal amino acid sequence. Anal Biochem. 1990;187:27-38.
20. Southan C. The use of glass capillary tubes as microbore columns for HPLC of proteins and peptides. In: Hugli T, ed. Techniques in Protein Chemistry. San Diego, Calif: Academic Press Inc; 1988:392-398.
21. Southan C. Fast, flexible, sensitive, and cheap: the use of home made microcolumns for the separation of proteins and peptides. J Protein Chem. 1994;13:461-462.
22. Buck MA, Olah TA, Weitzmann CJ, Cooperman BS. Protein estimation by the product of integrated peak area and flow rate. Anal Biochem. 1989;182:295-299.
23. Adams MD, Kelley JM, Gocayne JD, Dubnick M, Polymeropoulos MH, Xiao H, Merril CR, Wu A, Olde B, Moreno RF, Kerlavage AR, McCombie WR, Venter JC. Complementary DNA sequencing: expressed sequence tags and human genome project. Science. 1991;252:1651-1656.
24. Adams MD, Dubnick M, Kerlavage AR, Moreno R, Kelley JM, Utterback TR, Nagle JW, Fields C, Venter JC. Sequence identification of 2375 human brain genes. Nature. 1992;355:632-634.
25. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci U S A. 1984;81:1991-1995.
26. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. New York, NY: Cold Spring Harbor Laboratory Press; 1987.
27. Bullock WO, Fernandez JM, Short JM. XLl-blue: a high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection. Biotechniques. 1987;5:376-379.
28. Summers MD, Smith GE. A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures. Texas Agriculture Experiment Station Bulletin No. 1555; 1987.
29. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
30. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A. 1987;84:2995-2998.
31. Ostermann G, Ruhling K, Zabel-Langhennig R, Winkler L, Schlag B, Till U. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. Thromb Res. 1987;47:279-285.
32. Graham RM, Stephens CJ, Sturm MJ, Taylor RR. Plasma platelet-activating factor degradation in patients with severe coronary artery disease. Clin Sci (Colch). 1992;82:535-541.
33. Bairoch A. The PROSITE dictionary of sites and patterns in proteins: its current status. Nucleic Acids Res. 1993;21:3097-3103.
34. Derewenda ZS, Sharp AM. News from the interface: the molecular structures of triacylglyceride upases. Trends Biochem Sci. 1993;18:20-25.
35. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford, England: Clarendon Press; 1989:220-223.
36. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, Araki Y, Matsumoto M. Characterization of serum plate let-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest. 1988;82:1983-1991.
37. O'Connor WN, Davis JB Jr, Geissler R, Cottrill CM, Noonan JA, Todd EP. Supravalvular aortic stenosis: clinical and pathologic observations in six patients. Arch Pathol Lab Med. 1985;109:179-185.
38. Nakano T, Raines EW, Abraham JA, Klagsbrun M, Ross R. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc Natl Acad Sci U S A. 1994;91:1069-1073.
39. Kume N, Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994;93:907-911.